A Phase 1/2 interventional study of TAK-853 in Ovarian Cancer and Solid Tumors, sponsored by Takeda. Active, not recruiting at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Takeda · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. mirvetuximab soravtansine · Ovarian Neoplasms.
Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, this one is the 11th largest by enrollment, is the only one that started in 2024, is the only one in phase 1/2, and was the 9th registered.
3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →5 of the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Belgium and 5 more countries
Ages 18+ · Women only
Pheast Therapeutics · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18–100 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Women only
Tongji Hospital · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
mirvetuximab soravtansine: first FDA approval 2022 (ELAHERE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 2
First in 2016; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 80 across the 12 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 9 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
11 studies in Ovarian Neoplasms by Takeda: none open now, 1 under way, none of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 11 studies in Ovarian Neoplasms by Takeda, this one is the only one that started in 2024, is one of 2 in phase 1/2, and was the 11th registered.
Takeda’s Ovarian Neoplasms studies by the year they started, since 2002.
3 of the studies testing mirvetuximab soravtansine in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT05456685AbbVieMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | 2026-11 |
| NCT04606914University of Alabama at BirminghamStudy of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, from their registry updates:
Among Takeda’s 11 in Ovarian Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853 stays in their blood over time.
The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple times. In both phases, the participants will receive TAK-853 on the first days of each 3-week cycle.
The participant will be in the study for about 9 months in Phase 1 Part and for about 24 months in Phase 2 Part. The study doctors will check for side effects from the study treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1 part:
Diagnosis, allowable prior therapy, and disease measurability requirements:
All participants must have a documented, following advanced solid tumor known to express folate receptor alpha (FR alpha), that is resistant or to standard treatment, for which no standard treatment is available, or the participant refuses standard therapy.
Time from Prior Therapy:
Participants must have adequate hematologic, liver and kidney function as defined by the following parameters:
<!-- -->
Phase 2 part:
Participants must have platinum-resistant disease:
Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment:
a. +- adjuvant considered one line of therapy b. Maintenance therapy (e.g., bevacizumab, poly-ADP ribose polymerase [PARP] inhibitors) will be considered as part of the preceding line of therapy (i.e., not counted independently) c. Therapy changed due to toxicity in the absence of progression will be considered as part of the same line (i.e., not counted independently) d. Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance
Time from prior therapy:
Participants must have adequate hematologic, liver, and kidney functions defined as:
Exclusion Criteria:
Phase 1 part:
Serious concurrent illness, including, but not limited to the following:
active infection including - Active or C infection (whether or not on active antiviral therapy)
- (HIV) infection
- Active cytomegalovirus infection
- Active COVID-19/SARS-CoV-2 infection. Although SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines and standards
- Any other known concurrent infectious disease requiring IV antibiotics within 2 weeks before starting study drug Note: Testing at screening for hepatitis is required, while not required for the remaining infections above unless clinically indicated. Participants with known hepatitis B surface antigen seropositivity and/or detectable virus RNA will be excluded. Participants who have positive hepatitis B core antibody and/or hepatitis B surface antibody can be enrolled but must have an undetectable serum hepatitis B virus DNA. Participants who have positive hepatitis C virus antibody must have an undetectable hepatitis C virus RNA serum level. Participants will be monitored and managed according to Guideline for the prevention of therapy or chemotherapy-induced reactivation of hepatitis B virus infection (The Japan Society of Hepatology 2022).
Participants with clinically significant cardiac disease including, but not limited to, any one of the following:
- Myocardial infarction =\< 6 months prior to first dose of study medication
- Unstable angina pectoris
- Uncontrolled congestive heart failure ( > class II)
- Uncontrolled >= Grade 3 hypertension (per NCI CTCAE v5.0)
- Uncontrolled cardiac arrhythmias
- Severe aortic stenosis
Phase 2 part:
Participants with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:
Participants with known hepatitis B surface antigen seropositivity and/or detectable hepatitis C virus RNA will be excluded. Participants who have positive hepatitis B core antibody and/or hepatitis B surface antibody can be enrolled but must have an undetectable serum hepatitis B virus DNA.
Participants who have positive hepatitis C virus antibody must have an undetectable hepatitis C virus RNA serum level. Participants will be monitored and managed according to Guideline for the prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection (The Japan Society of Hepatology 2022).
7. Participants with history of multiple sclerosis or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome) 8. Participants with clinically significant cardiac disease including, but not limited to, any one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-853, 6.0 mg/kg, injection, intravenously (IV), once every 3 weeks. Patients will continue to receive study drug until disease progression, unacceptable toxicity, withdrawal of consent, death, or until the sponsor terminates the study (whichever comes first).
Drug: TAK-853
TAK-853 intravenous injection
Also known as: Mirvetuximab Soravtansine
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1
DLT was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and defined as any of following events: 1. If re-treatment was not initiated within 14 days due to adverse event (AE) related to protocol treatment; 2. Grade 4 neutropenia for more than 7 days; 3. Grade 3 or 4 neutropenia with single temperature reading \>= 38.3-degree Celsius (°C) or sustained temperature reading of greater than (\>) 38°C for \>1 hour; 4. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except following cases, AEs related to underlying disease, Alopecia, Grade 3 fatigue, Lymphopenia unless accompanied by clinically significant infection, isolated and asymptomatic Grade 3 abnormalities in biochemistry laboratory values that last for less than and equal to (\<=) 7 days including electrolyte abnormalities.
Time frame: Up to Cycle 1 (up to 21 days)
Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event, or a previous condition that has increased in severity or frequency since the administration of study drug.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity
The severity grade was evaluated as per the NCI CTCAE Version 5.0, where Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living \[ADL\]); Grade 3 was severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Grade 4 was life-threatening consequences; urgent intervention indicated, and Grade 5 was death related to AE. TEAEs were AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurs first.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 1: Number of Participants With Serious TEAEs
A serious TEAE is any untoward medical occurrence or effect that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, and was an important medical event.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 1: Number of Participants With TEAEs Leading to Drug Discontinuation
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to study drug discontinuation were reported.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 1: Number of Participants With TEAEs Leading to Infusion Interruption
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to infusion interruption were reported.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 1: Number of Participants With TEAEs Leading to Dose Delayed
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose delayed were reported.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 1: Number of Participants With TEAEs Leading to Dose Reduction
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose reduction were reported.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 1: Number of Participants With Adverse Event of Clinical Interest (AECIs)
AECIs (serious or nonserious) were those TEAEs which were of scientific and medical concern specific to the TAK-853. AECIs for TAK-853 included: 1. Ocular TEAEs, 2. Pneumonitis TEAEs, 3. Peripheral neuropathy TEAEs and 4. Infusion related TEAEs.
Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)
Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
ORR was defined as the percentage of participants who achieved a confirmed Partial Response (PR) or confirmed Complete Response (CR) during the study using RECIST 1.1. Complete response (CR): Disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 millimeters (mm). Partial response (PR): At least a 30% decrease in the sum of diameters (SoD of target lesions, taking as reference the baseline SoD).
Time frame: Up to 7.2 months
Phase 1: Maximum Observed Plasma Concentration (Cmax) of TAK-853 and Total Antibody (TAb)
Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. Cmax of TAK-853 and TAb were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Phase 1: Cmax of N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)- Maytansine (DM4) and S-methyl DM4
PK parameters were calculated using standard non-compartmental methods. Cmax of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Phase 1: Area Under the Plasma Concentration-Time Curve Until Tlast (AUClast) and Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of TAK-853 and TAb
PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of TAK-853 and TAb were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Phase 1: AUClast and AUCinf of DM4 and S-methyl DM4
PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Phase 1: Terminal Half-Life (t1/2) of TAK-853, TAb, DM4 and S-methyl DM4
PK parameters were calculated using standard non-compartmental methods. t1/2 of TAK-853, TAb, DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Phase 1: Total Clearance (CL) of TAK-853 and TAb
PK parameters were calculated using standard non-compartmental methods. CL of TAK-853 and TAb were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Phase 1: Apparent Clearance (CL/F) of DM4 and S-methyl DM4
PK parameters were calculated using standard non-compartmental methods. CL/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Phase 1: Volume of Distribution at Steady State (Vss) of TAK-853, TAb and Apparent Volume of Distribution During the Terminal Phase (VZ/F) of DM4 and S-methyl DM4
PK parameters were calculated using standard non-compartmental methods. Vss of TAK-853, TAb and VZ/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Number of Participants With Immunogenicity of TAK-853
Blood samples were collected to measure the presence of TAK-853 antibodies (ADA). Seronegative was defined as a participant with negative ADA at baseline and negative ADA at post-treatment. Treatment-emergent ADA was defined as a participant with negative ADA at baseline and positive ADA at post-treatment. Treatment-unaffected ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was less than or equal to 4-fold compared to baseline. Treatment-enhanced ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was greater than 4-fold compared to baseline.
Time frame: From start of study drug up to 8.2 months
Phase 2: Duration of Response (DOR) Assessed by Investigator With RECIST 1.1
DOR was defined as the time from the first observation of CR/PR (whichever is first recorded) to the first date at which progressive disease is objectively documented per RECIST 1.1, or death due to any cause, whichever occurs first. DOR was estimated using the Kaplan-Meier method.
Time frame: From first documented confirmed CR or PR until first documentation of PD (up to 7.2 months)
Phase 2: Plasma Concentrations of TAK-853 and TAb
Plasma concentrations of TAK-853 and TAb were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
Phase 2: Plasma Concentrations of DM4 and S-methyl DM4
Plasma concentrations of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
Time frame: Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
Participants took part in the study at 15 investigative sites in Japan from 20 May 2024.
| Milestone | Phase 1: TAK-853, 6 mg/kg | Phase 2: TAK-853, 6 mg/kg |
|---|---|---|
| Started | 3 | 25 |
| Completed | 3 | 0 |
| Not completed | 0 | 25 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Still on study | 0 | 24 |
DLT was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and defined as any of following events: 1. If re-treatment was not initiated within 14 days due to adverse event (AE) related to protocol treatment; 2. Grade 4 neutropenia for more than 7 days; 3. Grade 3 or 4 neutropenia with single temperature reading \>= 38.3-degree Celsius (°C) or sustained temperature reading of greater than (\>) 38°C for \>1 hour; 4. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except following cases, AEs related to underlying disease, Alopecia, Grade 3 fatigue, Lymphopenia unless accompanied by clinically significant infection, isolated and asymptomatic Grade 3 abnormalities in biochemistry laboratory values that last for less than and equal to (\<=) 7 days including electrolyte abnormalities.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 | 0 |
An AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event, or a previous condition that has increased in severity or frequency since the administration of study drug.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 3 |
The severity grade was evaluated as per the NCI CTCAE Version 5.0, where Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living \[ADL\]); Grade 3 was severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Grade 4 was life-threatening consequences; urgent intervention indicated, and Grade 5 was death related to AE. TEAEs were AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurs first.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity | 2 |
A serious TEAE is any untoward medical occurrence or effect that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, and was an important medical event.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With Serious TEAEs | 2 |
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to study drug discontinuation were reported.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With TEAEs Leading to Drug Discontinuation | 1 |
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to infusion interruption were reported.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With TEAEs Leading to Infusion Interruption | 0 |
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose delayed were reported.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With TEAEs Leading to Dose Delayed | 0 |
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose reduction were reported.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Phase 1: Number of Participants With TEAEs Leading to Dose Reduction | 0 |
AECIs (serious or nonserious) were those TEAEs which were of scientific and medical concern specific to the TAK-853. AECIs for TAK-853 included: 1. Ocular TEAEs, 2. Pneumonitis TEAEs, 3. Peripheral neuropathy TEAEs and 4. Infusion related TEAEs.
| Participants | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| Ocular TEAEs | 1 |
| Pneumonitis TEAEs | 0 |
| Peripheral neuropathy TEAEs | 2 |
| Infusion-related TEAEs | 0 |
ORR was defined as the percentage of participants who achieved a confirmed Partial Response (PR) or confirmed Complete Response (CR) during the study using RECIST 1.1. Complete response (CR): Disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 millimeters (mm). Partial response (PR): At least a 30% decrease in the sum of diameters (SoD of target lesions, taking as reference the baseline SoD).
| percentage of participants | Phase 2: TAK-853, 6 mg/kg |
|---|---|
| Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 44 (27.0 to 62.1) |
Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. Cmax of TAK-853 and TAb were reported at cycle 1 and cycle 3.
| micrograms per milliliter (mcg/mL) | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: TAK-853 | 128.3 ± 15.275 |
| At Cycle 1: TAb | 134.3 ± 21.962 |
| At Cycle 3: TAK-853 | 125.5 ± 4.9497 |
| At Cycle 3: TAb | 160.0 ± 16.971 |
PK parameters were calculated using standard non-compartmental methods. Cmax of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
| nanograms per milliliter (ng/mL) | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: DM4 | 5.360 ± 1.7317 |
| At Cycle 1: S-methyl DM4 | 10.04 ± 4.7816 |
| At Cycle 3: DM4 | 4.875 ± 1.3081 |
| At Cycle 3: S-methyl DM4 | 9.885 ± 4.1224 |
PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of TAK-853 and TAb were reported at cycle 1 and cycle 3.
| milligrams*hours/milliliter (mg*h/mL) | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| AUClast: At Cycle 1: TAK-853 | 14.19 ± 1.4178 |
| AUClast: At Cycle 1: TAb | 18.12 ± 1.7871 |
| AUClast: At Cycle 3: TAK-853 | 12.64 ± 1.8875 |
| AUClast: At Cycle 3: TAb | 22.03 ± 5.1276 |
| AUCinf: At Cycle 1: TAK-853 | 14.93 ± 1.5524 |
| AUCinf: At Cycle 1: TAb | 22.31 ± 1.7973 |
| AUCinf: At Cycle 3: TAK-853 | 15.52 ± 0.20264 |
| AUCinf: At Cycle 3: TAb | 35.77 ± 1.8223 |
PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
| nanograms*hours/milliliter (ng*h/mL) | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| AUClast: Cycle 1: DM4 | 243.8 ± 95.378 |
| AUClast: Cycle 1: S-methyl DM4 | 1935 ± 1279.3 |
| AUClast: Cycle 3: DM4 | 214.7 ± 58.406 |
| AUClast: Cycle 3: S-methyl DM4 | 1444 ± 368.31 |
| AUCinf: Cycle 1: DM4 | 258.9 ± 94.442 |
| AUCinf: Cycle 1: S-methyl DM4 | 2273 ± 1562.1 |
| AUCinf: Cycle 3: DM4 | 245.8 ± 69.877 |
| AUCinf: Cycle 3: S-methyl DM4 | 1909 ± 939.42 |
PK parameters were calculated using standard non-compartmental methods. t1/2 of TAK-853, TAb, DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
| hours | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: TAK-853 | 115.1 ± 6.3839 |
| At Cycle 1: TAb | 210.2 ± 44.702 |
| At Cycle 1: DM4 | 72.37 ± 12.508 |
| At Cycle 1: S-methyl DM4 | 158.9 ± 32.608 |
| At Cycle 3: TAK-853 | 130.3 ± 12.170 |
| At Cycle 3: TAb | 234.1 ± 51.979 |
| At Cycle 3: DM4 | 73.85 ± 18.392 |
| At Cycle 3: S-methyl DM4 | 121.5 ± 17.425 |
PK parameters were calculated using standard non-compartmental methods. CL of TAK-853 and TAb were reported at cycle 1 and cycle 3.
| milliliters per hour (mL/h) | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: TAK-853 | 21.04 ± 0.53430 |
| At Cycle 1: TAb | 14.09 ± 1.3011 |
| At Cycle 3: TAK-853 | 19.83 ± 2.5663 |
| At Cycle 3: TAb | 8.653 ± 1.6664 |
PK parameters were calculated using standard non-compartmental methods. CL/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
| liters per hour (L/h) | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: DM4 | 25.26 ± 8.6819 |
| At Cycle 1: S-methyl DM4 | 4.167 ± 3.4983 |
| At Cycle 3: DM4 | 24.41 ± 3.5361 |
| At Cycle 3: S-methyl DM4 | 3.381 ± 1.2256 |
PK parameters were calculated using standard non-compartmental methods. Vss of TAK-853, TAb and VZ/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
| liters (L) | Phase 1: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: TAK-853 | 3.135 ± 0.19878 |
| At Cycle 1: TAb | 3.854 ± 0.49267 |
| At Cycle 1: DM4 | 2532 ± 360.89 |
| At Cycle 1: S-methyl DM4 | 881.8 ± 644.96 |
| At Cycle 3: TAK-853 | 3.312 ± 0.19530 |
| At Cycle 3: TAb | 2.771 ± 0.072400 |
| At Cycle 3: DM4 | 2554 ± 271.07 |
| At Cycle 3: S-methyl DM4 | 577.3 ± 129.83 |
Blood samples were collected to measure the presence of TAK-853 antibodies (ADA). Seronegative was defined as a participant with negative ADA at baseline and negative ADA at post-treatment. Treatment-emergent ADA was defined as a participant with negative ADA at baseline and positive ADA at post-treatment. Treatment-unaffected ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was less than or equal to 4-fold compared to baseline. Treatment-enhanced ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was greater than 4-fold compared to baseline.
| Participants | Phase 1: TAK-853, 6 mg/kg | Phase 2: TAK-853, 6 mg/kg |
|---|---|---|
| Seronegative | 2 | 21 |
| Treatment-emergent ADA | 0 | 2 |
| Treatment-unaffected ADA | 1 | 2 |
| Treatment-enhanced ADA | 0 | 0 |
DOR was defined as the time from the first observation of CR/PR (whichever is first recorded) to the first date at which progressive disease is objectively documented per RECIST 1.1, or death due to any cause, whichever occurs first. DOR was estimated using the Kaplan-Meier method.
| months | Phase 2: TAK-853, 6 mg/kg |
|---|---|
| Phase 2: Duration of Response (DOR) Assessed by Investigator With RECIST 1.1 | NA (NA to NA) |
Plasma concentrations of TAK-853 and TAb were reported at cycle 1 and cycle 3.
| micrograms per milliliter (mcg/mL) | Phase 2: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: TAK-853 | 146.2 ± 29.513 |
| At Cycle 1: TAb | 138.6 ± 22.013 |
| At Cycle 3: TAK-853 | 145.2 ± 15.550 |
| At Cycle 3: TAb | 139.2 ± 25.606 |
Plasma concentrations of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
| nanograms per milliliter (ng/mL) | Phase 2: TAK-853, 6 mg/kg |
|---|---|
| At Cycle 1: DM4 | 3.352 ± 1.1023 |
| At Cycle 1: S-methyl DM4 | 0.3896 ± 0.78352 |
| At Cycle 3: DM4 | 3.076 ± 0.65073 |
| At Cycle 3: S-methyl DM4 | 3.428 ± 2.5061 |
Collected over From start of study drug up to 8.2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: TAK-853, 6mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 2: TAK-853, 6 mg/kg | 2/25 (8%) | 6/25 (24%) | 25/25 (100%) |
| Event | Phase 1: TAK-853, 6mg/kg | Phase 2: TAK-853, 6 mg/kg |
|---|---|---|
| Bile duct stenosisHepatobiliary disorders | 1/3 | 0/25 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/25 |
| Abdominal abscessInfections and infestations | 0/3 | 1/25 |
| Cholecystitis acuteHepatobiliary disorders | 0/3 | 1/25 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 1/25 |
| HeadacheNervous system disorders | 0/3 | 1/25 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 0/3 | 1/25 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 1/25 |
| Radius fractureInjury, poisoning and procedural complications | 0/3 | 1/25 |
| Event | Phase 1: TAK-853, 6mg/kg | Phase 2: TAK-853, 6 mg/kg |
|---|---|---|
| Neuropathy peripheralNervous system disorders | 2/3 | 0/25 |
| Alanine aminotransferase increasedInvestigations | 1/3 | 9/25 |
| NauseaGastrointestinal disorders | 0/3 | 9/25 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 8/25 |
| Back painMusculoskeletal and connective tissue disorders | 1/3 | 0/25 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 2/25 |
| KeratopathyEye disorders | 1/3 | 3/25 |
| Platelet count decreasedInvestigations | 1/3 | 6/25 |
| VomitingGastrointestinal disorders | 1/3 | 2/25 |
| Peripheral sensory neuropathyNervous system disorders | 0/3 | 7/25 |
The safety analysis set included the group of participants who received at least one dose of TAK-853.
| Age, Continuous(years) | Phase 1: TAK-853, 6mg/kg | Phase 2: TAK-853, 6 mg/kg | Total |
|---|---|---|---|
| Mean | 54.33 ± 16.289 | 65.56 ± 10.709 | 64.36 ± 11.58 |
| Sex: Female, Male(Participants) | Phase 1: TAK-853, 6mg/kg | Phase 2: TAK-853, 6 mg/kg | Total |
|---|---|---|---|
| Female | 3 | 25 | 28 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: TAK-853, 6mg/kg | Phase 2: TAK-853, 6 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 25 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1: TAK-853, 6mg/kg | Phase 2: TAK-853, 6 mg/kg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 25 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2024 to primary completion in Apr 2025, 10 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 10 months is below that.
Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirvetuximab soravtansine